OncoTargets and Therapy (Jul 2020)

Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports

  • Shi X,
  • Zhou J,
  • Qian C,
  • Gao L,
  • Wang B,
  • Feng X

Journal volume & issue
Vol. Volume 13
pp. 6789 – 6793

Abstract

Read online

Xuefei Shi, Jia Zhou, Caihua Qian, Liliang Gao, Bin Wang, Xueren Feng Department of Respiratory Medicine, Huzhou Centre Hospital, Affiliated Centre Hospital Huzhou University, Huzhou, People’s Republic of ChinaCorrespondence: Xueren FengDepartment of Respiratory Medicine, Huzhou Centre Hospital, Affiliated Centre Hospital Huzhou University, Huzhou, People’s Republic of ChinaTel/ Fax +86 572 2555775Email [email protected]: Lung cancer remains the leading cause of malignant tumor-related death globally. There is mounting evidence that a large proportion of patients harboring epidermal growth factor receptor (EGFR) mutation and treated with EGFR TKI experience oligoprogressive disease. The optimal treatment strategy for these patients is undetermined. Thus, in this article, we report two cases of EGFR-mutant NSCLC patients with locally resistant lesions achieving disease control via combination therapy.Patients and Methods: We present two cases of lung adenocarcinoma patients that developed oligoprogressive disease during TKI treatment. For further treatment, the patient then received radiofrequency ablation.Results: Through follow-up observation, we found that the addition of radiofrequency ablation might provide the clinical benefit of these two NSCLC patients.Conclusion: Our two cases provide a promising treatment for oligoprogressive disease during the first-line EGFR-TKI therapy.Keywords: radiofrequency ablation, EGFR-mutant non–small-cell lung cancer, oligoprogressive disease, first-line EGFR-TKI therapy

Keywords